Search
Tonix Pharmaceuticals Holding Corp
TNXPAdd to Watchlist
12.340USD
-0.100-0.80%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
157.80MMarket Cap
LossP/E TTM
More Details of Tonix Pharmaceuticals Holding Corp Company
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Tonix Pharmaceuticals Holding Corp Info
Ticker SymbolTNXP
Company nameTonix Pharmaceuticals Holding Corp
IPO dateMar 29, 2010
CEOLederman (Seth)
Number of employees81
Security typeOrdinary Share
Fiscal year-endMar 29
Address26 Main Street, Suite 101
CityCHATHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07928
Phone12129809155
Websitehttps://www.tonixpharma.com/
Ticker SymbolTNXP
IPO dateMar 29, 2010
CEOLederman (Seth)
Company Executives of Tonix Pharmaceuticals Holding Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Seth Lederman, M.D.
Dr. Seth Lederman, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
24.01K
+20.83%
Mr. Bradley Saenger, CPA
Mr. Bradley Saenger, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
701.00
--
Mr. James Treco
Mr. James Treco
Lead Independent Director
Lead Independent Director
250.00
--
Dr. Gregory M. (Greg) Sullivan, M.D.
Dr. Gregory M. (Greg) Sullivan, M.D.
Chief Medical Officer, Secretary
Chief Medical Officer, Secretary
--
--
Ms. Jessica Edgar Morris
Ms. Jessica Edgar Morris
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Margaret Smith Bell
Ms. Margaret Smith Bell
Independent Director
Independent Director
--
--
Maj. Gen. (Retd.) David L. Grange
Maj. Gen. (Retd.) David L. Grange
Independent Director
Independent Director
--
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
--
--
Mr. Richard H. (Rich) Bagger, J.D.
Mr. Richard H. (Rich) Bagger, J.D.
Independent Director
Independent Director
--
--
Ms. Carolyn E. Taylor
Ms. Carolyn E. Taylor
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Seth Lederman, M.D.
Dr. Seth Lederman, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
24.01K
+20.83%
Mr. Bradley Saenger, CPA
Mr. Bradley Saenger, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
701.00
--
Mr. James Treco
Mr. James Treco
Lead Independent Director
Lead Independent Director
250.00
--
Dr. Gregory M. (Greg) Sullivan, M.D.
Dr. Gregory M. (Greg) Sullivan, M.D.
Chief Medical Officer, Secretary
Chief Medical Officer, Secretary
--
--
Ms. Jessica Edgar Morris
Ms. Jessica Edgar Morris
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Margaret Smith Bell
Ms. Margaret Smith Bell
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Tonix Pharmaceuticals Holding Corp?
The top five shareholders of Tonix Pharmaceuticals Holding Corp are: Dr. Seth Lederman, M.D.
How many institutions hold shares of Tonix Pharmaceuticals Holding Corp (TNXP)?
As of 2026Q1, 177 institutions hold shares of Tonix Pharmaceuticals Holding Corp, with a combined market value of approximately 4.66M, accounting for 32.65% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2019652.00.